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the length of hospital stay (LOS).
Of all the patients (aged between 16 and 80 years) suffering from AP at the study hospital over a period of 26 months, a sample of 28 eligible patients was enrolled in the study. There were 14 patients in the group receiving TPN with glutamine (gln+) and 14 in the group receiving standard TPN (gln-). The patients in the gln+ group were aged 52.8 (+/-17.3) years and 7 were men. The weight in this group was 68 (+/-11.1 kg) and the body mass index (BMI) was 23.4 (+/-3.4) kg/m2. The patients in the gln-group were aged 54.8 (+/-18.1) years and 9 were men. The weight in this group was 69.5 (+/-11.3) kg and the BMI was 24.5 (+/-3.4) kg/m2. It was not stated whether some of the patients refused to participate or were excluded for any reason from the initial study sample.
Study design
This was a prospective randomised controlled trial that was conducted in a single centre. The method of randomisation was not reported. Patients, nurses and physicians were unaware of the patients' allocation to the study groups. The length of follow-up appears to have been 14 days. No patient was lost to follow-up.
Analysis of effectiveness
All of the patients included in the study were taken into account in the effectiveness analysis (intention to treat). The primary health outcomes used in the analysis were LOS and duration of TPN. The secondary health outcomes were infectious complication rate and variations in nutritional and inflammatory parameters. For example, leucocytes, lymphocytes, C-reactive protein, soluble tumour-necrosis factor alpha-receptor-p75, lipase, BMI, albumin, transferrin, protein, amino acid, glutamine serum cholinesterase activity, alkaline phosphatase, and alanine aminotransferase. The study groups were shown to be comparable at baseline.
Effectiveness results
The median length of TPN was 10 days (interquartile range: 6 -16) in the gln+ group and 16 days (interquartile range: 10 -18) in the gln-group, (p<0.05).
The median LOS was 21 days (interquartile range: 14 -32) in the gln+ group and 25 days (interquartile range: 19 -40) in the gln-group. This difference did not achieve statistical significance, (p>0.05).
The infectious complication rate was 29% in the gln+ group and 36% in the gln-group. The difference was not statistically significant.
Lymphocytes (10^3/microL) changed significantly from 1.2 (+/-0.6) to 1.9 (+/-0.8) in the gln+ group, and from 1.5 (+/-0.6) to 1.7 (+/-0.6) in the gln-group.
Glutamine serum cholinesterase changed significantly from 3.3 (+/-1.4) kU/L to 3.8 (+/-1.5) kU/L in the gln+ group, and from 3.5 (+/-0.9) kU/L to 3.7 (+/-1.6) kU/L in the gln-group. standard nutritional approach in patients with AP. You should decide whether it represents a widely used intervention in your own setting.
Validity of estimate of measure of effectiveness
The analysis of the effectiveness used a randomised controlled trial, which was appropriate for the study question. The study sample was representative of the study population. The study groups were shown to be comparable at baseline and statistical analyses were conducted when estimating the effectiveness. Retrospective power calculations were performed. These issues tend to increase the internal validity of the analysis. However, the authors stated that their analysis was underpowered to detect statistically significant differences in terms of secondary outcomes, such as complication rates. The method of randomisation was not reported.
Validity of estimate of measure of benefit
No summary benefit measure was used in the economic analysis. The analysis was therefore categorised as a costconsequences study.
Validity of estimate of costs
The perspective adopted in the study was not stated. Only the costs strictly related to the components of the solutions used for TPN were included in the analysis. The unit costs were not reported separately from the quantities of resources used and no price year was given, thus presenting difficulties for reflation exercises in other settings. Statistical analyses of the costs were performed, but the cost estimates were specific to the study setting as no sensitivity analyses were conducted.
